Today's Date: March 28, 2024
Carnegie Learning Wins 2024 EdTech Award for MATHstream   •   Federal Home Loan Bank of Dallas and Wells Fargo Bank Award $750K to CC Housing for Senior Affordable Housing Development   •   American Indian College Fund Invites Indigenous Academics, Administrators, and Student Services Personnel to Participate in High   •   Stora Enso publishes Green and Sustainability-Linked Financing Report 2023   •   Dr. Melissa Ivers Launches Prestigious Scholarship Recognizing Triumph Over Adversity   •   "SHAKIRA DESDE TIMES SQUARE," an Exclusive Special Taking Viewers Behind-the-Scenes of Shakira's Historic Surprise Performance i   •   Avocado Green Releases 2023 Impact & Sustainability Report, Highlighting Brand Leadership in Environmental and Social Respon   •   Universal Display Corporation Announces University Lecture Series and Participation and Sponsorship of OLED Korea Conference   •   ADM Names Commonwealth Warehouse Inc. as a 2023 Supplier Award Winner   •   Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows   •   KB Home Named to Newsweek’s 2024 List of America’s Most Trustworthy Companies for a Third Consecutive Year   •   Midea Group Breaks Revenue and Profit Records with RMB 373.7 Billion in 2023   •   Government of Canada signs two bilateral agreements with Quebec to support initiatives to improve health care   •   The Lenserf Group Launches Emotional Intelligence Academy for HBCU Interns   •   Family Source Consultants Celebrates Michigan Legislature Passing Landmark Fertility Health Care Act (House Bill 5207) to Legali   •   EIG’s MidOcean Energy Completes Acquisition of Tokyo Gas’ Interests in Portfolio of Australian Integrated LNG Projec   •   Compass Minerals Announces Amendment to Credit Agreement   •   MDWerks’ Two Trees Beverage Subsidiary to Kick Off Co-Sponsorship of Team Combat League in TCL’s Second Season Debut   •   Guo Guangchang: "Focus on building sustainable, predictable and enterprise with stable profit growth "   •   SLB Announces Agreement to Acquire Majority Ownership in Aker Carbon Capture
Bookmark and Share

Evofem Biosciences Announces Approval of Phexxi in Nigeria

Evofem Biosciences Announces Approval of Phexxi in Nigeria

PR Newswire

-- First Regulatory Approval Outside the U.S. --

SAN DIEGO, Oct. 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that its hormone-free contraceptive vaginal gel has been approved by the Nigerian Regulatory Agency NAFDAC (National Agency for Food and Drug Administration and Control). 

This marks the Company's first approval outside the United States. Regulatory dossiers have also been submitted in Ghana, Ethiopia and Mexico. The product will be potentially marketed under the brand name Femidence™.   

Nigeria is the most populous country in Africa and the seventh largest country in the world, with 45 million women of reproductive age. With nearly half of the population under the age of 18 years, a record number of young people will enter reproductive age in the next decade.

In October 2020, Adjuvant Capital made a $25 million strategic investment to expand global market access for Phexxi® (lactic acid, citric acid, potassium bitartrate) vaginal contraceptive gel and to support EVOGUARD, Evofem's registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women. Evofem is on track to report top-line data from this landmark trial in mid-October 2022. Positive study outcomes would enable regulatory submissions and potential U.S. approval for prevention of these sexually transmitted infections in 2023. 

"We expect Nigeria will be one of many commercial markets around the world in which Evofem can generate shareholder returns while favorably impacting the lives of women," said Jenny Yip, Managing Partner at Adjuvant Capital and a Director of Evofem Biosciences. "Women everywhere are demanding more contraceptive choices to suit their needs, and they specifically want non-hormonal options, like Phexxi, that are free from common side effects like depression, mood swings and irritability." 

Evofem is grateful to DKT Nigeria, its distribution partner in Nigeria, for their support of this registration.

About Evofem Biosciences

Evofem Biosciences, Inc. is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data in mid-October 2022 from its registrational Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark and Femidence™ is a trademark of Evofem Biosciences, Inc.

Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Various factors could cause actual results to differ materially from those discussed or implied in the forward-looking statements, including our ability to successfully commercialize Phexxi outside of the U.S. and general market and other conditions, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements, or that could impair the value of Evofem Biosciences' assets and business, are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2021, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022,  and subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contacts

Investors:

Amy Raskopf

SVP, Investor Relations

Evofem Biosciences, Inc.

araskopf@evofem.com

(917) 673-5775

Media:

media@evofem.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-announces-approval-of-phexxi-in-nigeria-301642132.html

SOURCE Evofem Biosciences, Inc.



Back to top
| Back to home page
Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News